Compare HWKN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | ADPT |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 1995 | 2019 |
| Metric | HWKN | ADPT |
|---|---|---|
| Price | $147.99 | $14.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $200.00 | $17.78 |
| AVG Volume (30 Days) | 139.2K | ★ 2.0M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | 12.26 | ★ 63.89 |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $974,431,000.00 | $276,976,000.00 |
| Revenue This Year | $12.37 | $3.98 |
| Revenue Next Year | $6.30 | $22.72 |
| P/E Ratio | $47.40 | ★ N/A |
| Revenue Growth | 6.01 | ★ 54.77 |
| 52 Week Low | $117.51 | $6.77 |
| 52 Week High | $186.15 | $20.76 |
| Indicator | HWKN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 52.25 |
| Support Level | $142.77 | $12.19 |
| Resistance Level | $154.95 | $17.72 |
| Average True Range (ATR) | 5.01 | 0.99 |
| MACD | -0.15 | 0.14 |
| Stochastic Oscillator | 31.34 | 70.42 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.